If you walk onto the UMCG site from the Oostersingel, you will see Sanquin at entrance 47. Sanquin is the national organization responsible for the blood supply in the Netherlands. They ensure that there is enough blood and blood products available for hospitals and other healthcare institutions. Since 2005, Sanquin has been located on the Healthy Ageing Campus in Groningen. Campus Groningen once visited this player on campus, which is the only organization in the Netherlands tasked by the ministry with ensuring the blood supply.
More demand for plasma donors
With over 400,000 active blood donors in the Netherlands, 2 out of 100 residents currently donate blood voluntarily. This helps about 100,000 patients annually. “That is of course fantastic,” says Karin Zuidema, location manager at Sanquin. “And currently the biggest challenge for Sanquin is recruiting enough plasma donors.” The demand for blood plasma increases by about 3% annually, while the demand for blood cells decreases. "We therefore ask some of our blood donors if they want to donate plasma. This takes a little more time, but it is essential for helping patients." Plasma consists of fluid and proteins and can be administered to patients with burns. The proteins can also serve as raw material for medicines.
"And currently the biggest challenge for Sanquin is recruiting enough plasma donors.” The demand for blood plasma increases by about 3% annually, while the demand for blood cells decreases. "We therefore ask some of our blood donors if they want to donate plasma. This takes a little more time, but it is essential for helping patients."
Karin Zuidemalocation manager at Sanquin
A careful process
How does that work? The process of blood and plasma donation at Sanquin is careful and efficient. Donors undergo an examination to determine whether it is safe (both for themselves and the recipient) to donate. In plasma donation, the plasma is separated from the blood cells. The donor then receives the blood cells back through the same needle. This causes less fatigue and the donated proteins and fluid are quickly replenished by the body. Therefore, donating plasma can be done more frequently than donating blood. All collected blood is sent to Nijmegen for processing. The blood products obtained there are then returned to Groningen for distribution to hospitals in Groningen and Drenthe.
The road to self-sufficient production
Thanks to Sanquin and Dutch donors, the Netherlands is self-sufficient in terms of blood transfusion products. But this does not apply to plasma as a basis for plasma medicines. In this area, the Netherlands still partly depends on imports of plasma medicines from international manufacturers. Looking to the future, Sanquin aims to make the Netherlands more self-sufficient in meeting the demand for plasma medicines.
On the Healthy Ageing Campus, Sanquin contributes to the mission of promoting healthy aging through regular health checks of donors, innovative products such as the development of eye drops from donor blood and scientific research in the field of anemia, blood clotting, immunotherapy and immunity & inflammation. Sanquin is also a founder of the Health Innovation District in Amsterdam, where companies within the biomedical sector are brought together to further innovate healthcare together.
The proximity of UMCG offers Sanquin significant advantages, including direct access to advanced medical facilities and close collaboration with leading researchers and specialists. This allows them to collaborate more quickly and efficiently on new medical insights and technologies, benefiting the quality of services and research on both sides.
Source article: Campus Groningen Pictures: own images Sanquin
Op zondag 31 mei 2026 staat Groningen in het teken van sport, doorzettingsvermogen en betrokkenheid. Tussen alle lopers is ook het herkenbare roze van Vrienden Beatrix Kinderziekenhuis zichtbaar.
The LIFE Cooperative, part of the Northern Netherlands life sciences ecosystem at Campus Groningen, is organizing the Dutch Medicines Winter Afternoon together with FIGON on Thursday, 26 February. This fully booked event brings together leading scientists and industry experts to explore the latest developments in innovative medicines and advanced drug delivery. Read the full article as published by the LIFE Cooperative.National Attention for Sold-Out Dutch Medicines Winter Afternoon: Innovative Medicines and Advanced Drug Delivery Take Center Stage in Groningen Innovation in medicines takes center stage on Thursday, 26 February during the Dutch Medicines Winter Afternoon, an inspiring event organized by FIGON (Federation for Innovative Drug Research Netherlands) in collaboration with the LIFE Cooperative. “We are extremely proud of the strong line-up at this event, bringing together leading experts from science and industry to explore the frontiers of drug development. The fact that registrations are already fully booked underlines the great importance of this event for the life sciences ecosystem, and in particular for the Northern Netherlands,” says Ronald Hesse, Director of the LIFE Cooperative. The Dutch Medicines Winter Afternoon brings together scientists, innovators, and professionals from across the Netherlands for an afternoon of insights, knowledge exchange, and networking opportunities. The speaker line-up features experts from both academia and industry. This event is already fully booked. Interested in joining the waiting list? Please email: amber@lifecooperative.nlConnecting force The afternoon will be opened by Prof. Klaas Poelstra of the University of Groningen (RUG), Chair of FIGON, who will outline the importance of innovative drug development in the Netherlands. This will be followed by an introduction by Robert Hof on behalf of the LIFE Cooperative, highlighting the cooperative’s role as a connecting force within the regional ecosystem. The first session block before the break focuses on innovation in drug delivery systems. Rob Steendam (CTO, InnoCore) will discuss the development of long-acting SynBiosys® microspheres for controlled and sustained drug release. Jaap Wieling (CEO, PureIMS) will present the potential of dry-powder inhalation via the Cyclops® technology for both pulmonary and systemic indications. From an academic perspective, Prof. Marleen Kamperman (University of Groningen) will explore the potential of polyelectrolyte coacervates as innovative drug delivery platforms.Deep dive After the break, the focus shifts to advanced nanomedicines and clinical development strategies. Dr. Flávia Sousa (RUG) will present her work on polymer-based nanomedicines for the delivery of biotherapeutics to the brain. Dr. Ad Roffel (ICON plc, Groningen) will address mass balance and absolute bioavailability studies with ¹⁴C-labeled drugs in humans, an essential component of clinical drug development. Prof. Erik Frijlink (RUG) will reflect on the value of innovation within both established and advanced drug delivery systems, placing technological progress in a broader pharmaceutical context. Finally, Prof. Helder Santos (RUG) will demonstrate how nanomedicines are being used for RNA delivery in myocardial infarction repair, a promising development in cardiovascular therapy. “We are extremely proud of the strong line-up at this event, bringing together leading experts from science and industry to explore the frontiers of drug development. The fact that registrations are already fully booked underlines the great importance of this event for the life sciences ecosystem, and in particular for the Northern Netherlands." - Ronald Hesse, director LIFE CooperativeClosing and networking The afternoon will conclude with a contribution by Peter Ketelaar (LIFE Cooperative), followed by closing remarks from Prof. Klaas Poelstra. Participants will then have the opportunity to connect and continue discussions during the networking reception. Hesse looks forward to the event: “With this event, FIGON and the LIFE Cooperative underline the strength of collaboration between academia, industry, and clinical practice. The Dutch Medicines Winter Afternoon promises not only to be an inspiring afternoon, but also to provide momentum for further innovation and collaboration within the Northern Netherlands life sciences ecosystem.” Text: lifecooperative.nlPhotographer: Casper Maas
The master plan for the Healthy Ageing Campus has officially been approved! This marks an important step in developing the campus as a hub for knowledge, innovation, and collaboration. With a focus on greenery, health, and connection to the city, the campus will become a vibrant environment where research, education, healthcare, and business come together. The vision provides space for new laboratories, building renovations, meeting places, and closer collaboration between UMCG, RUG, and the business community. Read the whole article by the UMCG below.Green light for the Healthy Ageing Campus Master Plan On Wednesday, 18 February 2026, the Groningen City Council formally approved the master plan for the Healthy Ageing Campus. This is a major milestone, as the plan provides the framework for the campus’s further development and its integration with the surrounding area. At the end of last year, the University of Groningen (RUG), the University Medical Center Groningen (UMCG), and the City of Groningen presented an ambitious, future-proof plan for the campus. Shared ambitions have been translated into coherent spatial and programmatic guidelines for current and future developments. In other words: how much space is available for which functions on the campus, and where is the most suitable location for them? The renewed campus will: Provide space for knowledge, innovation, and collaboration, encouraging interaction between disciplines and people; Connect with the city, making the campus a natural part of Groningen life; Be a healthy and sustainable environment, with attention to greenery, physical activity, wellbeing, and a living environment that supports health; Be lively and accessible, bringing together living, working, research, studying, and healthcare.Next steps The master plan is not only a blueprint for the future, but also a concrete step toward further developing the current campus. Construction and renovation on the UMCG and RUG grounds are ongoing, and each project must now be assessed to determine what is possible. With the approval of this master plan, the way is cleared for follow-up decisions, including applying for demolition and building permits and further project development within the area. Upcoming projects include: The construction of the Central Laboratory for Diagnostics and Research (CLDR): a new laboratory building on the site of the former UCP building. This building will bring together various laboratories in one location to improve collaboration. Relocating laboratories from the Central Medical Complex is also necessary for the renovation and expansion of several hospital departments; Renovation and future-proofing of existing UMCG and RUG buildings, with attention to sustainability, flexibility, and integration with the heating/cooling system; Making the campus greener and more accessible, creating new meeting places and better connections to surrounding public spaces; Creating space for campus-related business activities, strengthening collaboration between UMCG, RUG, and the private sector.Municipality explores the future of DOT Initially, the master plan covered the area between Petrus Campersingel and Oostersingel, from Hanzeplein to the Oosterhamrikkanaal. In the newly approved plan, the Bodenterrein site has been separated, as the municipality is investigating the costs of possibly preserving DOT. More information on this will be available later this year. Read more about the Master Plan.Source text and pictures: umcg.nl
